These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37436237)

  • 21. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients.
    Piotto D; Nicacio A; Neto A; Mourão AF; Oliveira-Ramos F; Campanilho-Marques R; Guedes M; Cabral M; Santos MJ; Fonseca JE; Canhão H; Aikawa NE; Oliveira SKF; Ferriani VPL; Pileggi GCS; Magalhães CS; Silva CA; Terreri MT
    Adv Rheumatol; 2022 Jun; 62(1):20. PubMed ID: 35689240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
    Iannone F; Cantini F; Lapadula G
    J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
    Tang I; So H; Luk L; Wong V; Pang S; Lao V; Yip R
    Hong Kong Med J; 2020 Apr; 26(2):111-119. PubMed ID: 32245912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases.
    Özlü C; Türkuçar S; Asrak HK; Dündar HA; Ünsal ŞE; Belet N
    Turk J Pediatr; 2021; 63(6):978-985. PubMed ID: 35023647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
    Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
    Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain.
    Calzada-Hernández J; Anton J; Martín de Carpi J; López-Montesinos B; Calvo I; Donat E; Núñez E; Blasco Alonso J; Mellado MJ; Baquero-Artigao F; Leis R; Vegas-Álvarez AM; Medrano San Ildefonso M; Pinedo-Gago MDC; Eizaguirre FJ; Tagarro A; Camacho-Lovillo M; Pérez-Gorricho B; Gavilán-Martín C; Guillén S; Sevilla-Pérez B; Peña-Quintana L; Mesa-Del-Castillo P; Fortuny C; Tebruegge M; Noguera-Julian A
    Eur J Pediatr; 2023 Jan; 182(1):307-317. PubMed ID: 36335186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biologicals for children and adolescents in the treatment of rheumatic diseases].
    Huppertz HI
    Z Rheumatol; 2012 Sep; 71(7):583-9; quiz 590-1. PubMed ID: 22930109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.
    Noguera-Julian A; Calzada-Hernández J; Brinkmann F; Basu Roy R; Bilogortseva O; Buettcher M; Carvalho I; Chechenyeva V; Falcón L; Goetzinger F; Guerrero-Laleona C; Hoffmann P; Jelusic M; Niehues T; Ozere I; Shackley F; Suciliene E; Welch SB; Schölvinck EH; Ritz N; Tebruegge M
    Clin Infect Dis; 2020 Dec; 71(10):2561-2569. PubMed ID: 31796965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
    Wang PH; Lin CH; Chang TH; Wu CS
    BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
    Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
    Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
    Pyo J; Cho SK; Kim D; Sung YK
    Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.
    Prieto-Peña D; Dasgupta B
    Pol Arch Intern Med; 2021 Feb; 131(2):171-181. PubMed ID: 32550671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.
    Nobre CA; Callado MR; Lima JR; Gomes KW; Martiniano GV; Vieira WP
    Rheumatol Int; 2012 Sep; 32(9):2769-75. PubMed ID: 21822912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
    Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
    Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.